Project description
New Alzheimer’s disease biomarkers
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no cure or interventions to modify its course. Research and development of new treatments has been hampered by the lack of accurate diagnostic tools that can identify individuals in the early stages of AD. Funded by the Marie Skłodowska-Curie Actions programme, the BBDiag project aims to address this limitation by identifying AD biomarkers and developing specific detection methods. The project brings together European experts in the field who will also provide interdisciplinary training for young researchers. Ultimately, the goal is to design disease-modifying treatments and improve care of individuals with AD.
Objective
Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in clinical drug intervention trials is among the main reasons for many notable trial failures. The main challenges in developing the required diagnostics are identification of AD biomarkers and development of their detection techniques. The complex and interdisciplinary nature of the research underlines the need for innovative training of a new generation of researchers in the field. BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial experts from five major consortia in Europe and uses their synergies to build a triple-i research & training platform with the required multidisciplinary expertise and cutting-edge technologies. BBDiag Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary scientific and transferable skills as well as personal quality, creative thinking and business mind-set. The ETN has a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag will deliver its first generation of 13 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.
Fields of science
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- engineering and technologynanotechnologynano-materialstwo-dimensional nanostructuresgraphene
- medical and health sciencesbasic medicinepathology
- medical and health scienceshealth sciencespublic healthepidemiologymodeling of diseases spread
Programme(s)
Coordinator
PL4 8AA Plymouth
United Kingdom